Report cover image

AI In Oncology Market Size, Share & Trends Analysis Report By Component Type (Software Solutions, Hardware), By Cancer Type (Breast Cancer, Lung Cancer), By Application (Diagnostics, Radiation Therapy), By End Use, By Region, And Segment Forecasts, 2026 -

Publisher Grand View Research
Published Dec 22, 2025
Length 150 Pages
SKU # GV20723887

Description

AI In Oncology Market Summary

The global AI in oncology market size was estimated at USD 6.00 billion in 2025 and is expected to reach USD 38.91 billion by 2033, growing at a CAGR of 24.77% from 2026 to 2033. The growth of the market is attributed to increasing prevalence of cancer, technological advancement in cancer diagnostics & healthcare infrastructure, and an increasing demand for early detection and classification of cancer.

In addition, rising adoption of precision medicine is drives market growth further. The increasing incidence of cancer globally has led to a growing dependence on AI in the field of oncology. According to the NIH estimates of 2023, approximately 2.0 million individuals in the U.S. are diagnosed with cancer. Breast cancer was the most diagnosed cancer, with an estimated 297,790 cases in women and 2,800 cases in men. Among men, prostate cancer was the most frequently diagnosed cancer, and overall, it was the second most common diagnosis, with an anticipated 288,300 cases. The estimated number of new cases of lung and bronchus cancer made it the third most diagnosed cancer.

The growing initiatives undertaken by public and private organizations to invest in research and development (R&D) for introduction of novel technologies are further anticipated to fuel growth of the market. For instance, in October 2022, Tempus, a company specializing in precision medicine and AI, recently announced a program called Tempus+. This proprietary program utilizes real-world data to power collaborative precision oncology research. A community of researchers, including Baylor College of Medicine, Allegheny Health Network, Stanford Cancer Center, Rush University Medical Center, TriHealth, and others, is already using the Tempus+ program to advance their research. Furthermore, increasing product approval of AI-associated medical devices is anticipated to boost market growth. In January 2024, the U.S. FDA approved the first AI medical device, DermaSensor, to detect skin cancer.

The future of AI applications in cancer care is poised for groundbreaking advancements, encompassing early detection, precision medicine, and personalized treatment plans. AI's ability to analyze vast datasets, identify subtle patterns, and provide real-time insights holds the potential to revolutionize cancer diagnosis and therapy, ushering in a new era of improved patient outcomes and more efficient healthcare delivery.

Global AI In Oncology Market Report Segmentation

This report forecasts revenue growth and provides at global, regional, and country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global AI in oncology market report based on component type, cancer type, application, end use, and region:
  • Component Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Software Solutions
  • Hardware
  • Services
  • Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Brain Tumor
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Diagnostics (Pathology, Cancer Radiology)
  • Radiation therapy (Radiotherapy)
  • Research & Development (Drug design, development process, etc.)
  • Chemotherapy
  • Immunotherapy
  • End Use Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals
  • Surgical Centers & Medical Institutes
  • Others (Pharmaceutical companies, Research institutes & training centers)
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

150 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Application
1.3. Research Methodology
1.4. Information Procurement
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Microbiology & Bacterial Culture Media Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Growth in global food microbiology testing
3.2.1.2. Rising need for high-quality culture media for diagnostic applications
3.2.1.3. Continuous advancements in biopharmaceutical manufacturing
3.2.2. Market restraint analysis
3.2.2.1. High cost of advanced or specialty media
3.2.2.2. Growing preference for alternative methods like molecular diagnostics
3.3. Microbiology & bacterial culture media market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. Microbiology & Bacterial Culture Media Market: Product Estimates & Trend Analysis
4.1. Product Segment Dashboard
4.2. Global Microbiology & Bacterial Culture Media Market Product Movement Analysis
4.3. Global Microbiology & Bacterial Culture Media Market Size & Trend Analysis, by Product, 2021 - 2033 (USD Million)
4.4. Dehydrated Culture Media
4.4.1. Dehydrated Culture Media Market Size & Forecasts and Trend Analysis, 2021 - 2033 (USD Million)
4.5. Ready-to-use Media
4.5.1. Ready-to-use Media Market Size & Forecasts and Trend Analysis, 2021 - 2033 (USD Million)
Chapter 5. Microbiology & Bacterial Culture Media Market: Application Estimates & Trend Analysis
5.1. Application Segment Dashboard
5.2. Global Microbiology & Bacterial Culture Media Market Application Movement Analysis
5.3. Global Microbiology & Bacterial Culture Media Market Size & Trend Analysis, by Application, 2021 - 2033 (USD Million)
5.4. Pharmaceutical & Biopharmaceutical Production
5.4.1. Pharmaceutical & Biopharmaceutical Production Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
5.5. Diagnostics
5.5.1. Diagnostics Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
5.6. Food & Water Testing
5.6.1. Food & Water Testing Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
5.6.2. Food
5.6.2.1. Food Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
5.6.3. Animal Feed
5.6.3.1. Animal Feed Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
5.6.4. Water Testing
5.6.4.1. Water Testing Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
5.7. Bioenergy & Agricultural Research
5.7.1. Bioenergy & Agricultural Research Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
5.8. Cosmetics and Personal Care Applications
5.8.1. Cosmetics and Personal Care Applications Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
5.9. Others
5.9.1. Others Market Size & Forecasts and Trend Analyses, 2021 - 2033 (USD Million)
Chapter 6. Microbiology & Bacterial Culture Media Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2025 & 2033
6.2. Regional Market Dashboard
6.3. North America
6.3.1. U.S.
6.3.1.1. Key country dynamics
6.3.1.2. Regulatory framework
6.3.1.3. Competitive scenario
6.3.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
6.3.2. Canada
6.3.2.1. Key country dynamics
6.3.2.2. Regulatory framework
6.3.2.3. Competitive scenario
6.3.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
6.3.3. Mexico
6.3.3.1. Key country dynamics
6.3.3.2. Regulatory framework
6.3.3.3. Competitive scenario
6.3.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
6.4. Western Europe
6.4.1. UK
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework
6.4.1.3. Competitive scenario
6.4.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.2. Germany
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework
6.4.2.3. Competitive scenario
6.4.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.3. France
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework
6.4.3.3. Competitive scenario
6.4.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.4. Italy
6.4.4.1. Key country dynamics
6.4.4.2. Regulatory framework
6.4.4.3. Competitive scenario
6.4.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.5. Spain
6.4.5.1. Key country dynamics
6.4.5.2. Regulatory framework
6.4.5.3. Competitive scenario
6.4.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.6. Norway
6.4.6.1. Key country dynamics
6.4.6.2. Regulatory framework
6.4.6.3. Competitive scenario
6.4.6.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.7. Sweden
6.4.7.1. Key country dynamics
6.4.7.2. Regulatory framework
6.4.7.3. Competitive scenario
6.4.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
6.4.8. Denmark
6.4.8.1. Key country dynamics
6.4.8.2. Regulatory framework
6.4.8.3. Competitive scenario
6.4.8.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
6.5. Eastern Europe
6.5.1. Poland
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework
6.5.1.3. Competitive scenario
6.5.1.4. Poland market estimates and forecasts, 2021 - 2033 (USD Million)
6.5.2. Hungary
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework
6.5.2.3. Competitive scenario
6.5.2.4. Hungary market estimates and forecasts, 2021 - 2033 (USD Million)
6.5.3. Czech Republic
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework
6.5.3.3. Competitive scenario
6.5.3.4. Czech Republic market estimates and forecasts, 2021 - 2033 (USD Million)
6.5.4. Bulgaria
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework
6.5.4.3. Competitive scenario
6.5.4.4. Bulgaria market estimates and forecasts, 2021 - 2033 (USD Million)
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework
6.6.1.3. Competitive scenario
6.6.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
6.6.2. China
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework
6.6.2.3. Competitive scenario
6.6.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
6.6.3. India
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework
6.6.3.3. Competitive scenario
6.6.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
6.6.4. Australia
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework
6.6.4.3. Competitive scenario
6.6.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
6.6.5. South Korea
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework
6.6.5.3. Competitive scenario
6.6.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
6.7. Southeast Asia
6.7.1. Thailand
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework
6.7.1.3. Competitive scenario
6.7.1.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
6.7.2. Vietnam
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework
6.7.2.3. Competitive scenario
6.7.2.4. Vietnam market estimates and forecasts, 2021 - 2033 (USD Million)
6.7.3. Indonesia
6.7.3.1. Key country dynamics
6.7.3.2. Regulatory framework
6.7.3.3. Competitive scenario
6.7.3.4. Indonesia market estimates and forecasts, 2021 - 2033 (USD Million)
6.7.4. Singapore
6.7.4.1. Key country dynamics
6.7.4.2. Regulatory framework
6.7.4.3. Competitive scenario
6.7.4.4. Singapore market estimates and forecasts, 2021 - 2033 (USD Million)
6.8. Latin America
6.8.1. Brazil
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework
6.8.1.3. Competitive scenario
6.8.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
6.8.2. Argentina
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework
6.8.2.3. Competitive scenario
6.8.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
6.9. MEA
6.9.1. South Africa
6.9.1.1. Key country dynamics
6.9.1.2. Regulatory framework
6.9.1.3. Competitive scenario
6.9.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
6.9.2. Saudi Arabia
6.9.2.1. Key country dynamics
6.9.2.2. Regulatory framework
6.9.2.3. Competitive scenario
6.9.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
6.9.3. UAE
6.9.3.1. Key country dynamics
6.9.3.2. Regulatory framework
6.9.3.3. Competitive scenario
6.9.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
6.9.4. Kuwait
6.9.4.1. Key country dynamics
6.9.4.2. Regulatory framework
6.9.4.3. Competitive scenario
6.9.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company/Competition Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2025
7.4. Company Profiles/Listing
7.4.1. Merck KGaA
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. bioMérieux SA
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. HiMedia Laboratories
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. Thermo Fisher Scientific Inc.
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. BD
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Solabia Group (Biokar diagnostics)
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Titan Biotech Ltd.
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. CONDALAB
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Neogen Corporation
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Bio-Rad Laboratories, Inc.
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. SHIMADZU
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives
7.4.12. Hardy Diagnostics
7.4.12.1. Company overview
7.4.12.2. Financial performance
7.4.12.3. Product benchmarking
7.4.12.4. Strategic initiatives
7.4.13. R-Biopharm AG
7.4.13.1. Company overview
7.4.13.2. Financial performance
7.4.13.3. Product benchmarking
7.4.13.4. Strategic initiatives
7.4.14. Alpha Teknova, Inc.
7.4.14.1. Company overview
7.4.14.2. Financial performance
7.4.14.3. Product benchmarking
7.4.14.4. Strategic initiatives
7.4.15. MP Biomedicals
7.4.15.1. Company overview
7.4.15.2. Financial performance
7.4.15.3. Product benchmarking
7.4.15.4. Strategic initiatives
7.4.16. Micromaster Laboratories Pvt. Ltd.
7.4.16.1. Company overview
7.4.16.2. Financial performance
7.4.16.3. Product benchmarking
7.4.16.4. Strategic initiatives
7.4.17. ELEX Biological Products (Shanghai) Co., Ltd.
7.4.17.1. Company overview
7.4.17.2. Financial performance
7.4.17.3. Product benchmarking
7.4.17.4. Strategic initiatives
7.4.18. Eiken Chemical Co., Ltd.
7.4.18.1. Company overview
7.4.18.2. Financial performance
7.4.18.3. Product benchmarking
7.4.18.4. Strategic initiatives

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us